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Gillespie syndrome (GS) is a rare variant form of aniridia characterized by non-progressive cerebellar ataxia, intellectual disability, and iris
hypoplasia. Unlike themore common dominant and sporadic forms of aniridia, there has been no significant associationwith PAX6mu-
tations in individualswithGSand themodeof inheritanceof thediseasehad longbeen regarded asuncertain.Using a combinationof trio-
basedwhole-exome sequencing and Sanger sequencing in five simplexGS-affected families, we foundhomozygous or compoundhetero-
zygous truncating mutations (c.4672C>T [p.Gln1558*], c.2182C>T [p.Arg728*], c.6366þ3A>T [p.Gly2102Valfs5*], and c.6664þ5G>T
[p.Ala2221Valfs23*]) and de novo heterozygous mutations (c.7687_7689del [p.Lys2563del] and c.7659T>G [p.Phe2553Leu]) in the
inositol 1,4,5-trisphosphate receptor type 1 gene (ITPR1). ITPR1 encodes one of the three members of the IP3-receptors family that
formCa2þ release channels localizedpredominantly inmembranes of endoplasmic reticulumCa2þ stores. The truncationmutants,which
encompass the IP3-bindingdomain andvarying lengthsof themodulatory domain, didnot form functional channelswhenproduced in a
heterologous cell system. Furthermore, ITPR1 p.Lys2563del mutant did not form IP3-induced Ca
2þ channels but exerted a negative effect
when co-producedwithwild-type ITPR1 channel activity. In total, these results demonstrate biallelic andmonoallelic ITPR1mutations as
the underlying genetic defects for Gillespie syndrome, further extending the spectrum of ITPR1-related diseases.Aniridia (MIM: 106210) refers to a rare inborn error of eye
development whose most prominent sign is the partial or
complete absence of iris. Associated ocular malformations
include macular and optic nerve hypoplasia, cataract, and
corneal opacification. Most aniridia cases are accounted for
by dominant mutations affecting PAX6 (MIM: 607108) at
the AN locus (MIM: 106210).1 Wilms tumor, genitourinary
abnormalities, and intellectual disability are not uncom-
mon in individuals with aniridia. This complex form of
the disease known as WAGR syndrome (MIM: 194072)
has been ascribed to 11q13 deletions involving the PAX6
locus and the adjacent Wilms tumor 1 (WT1) locus
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ataxia and intellectual disability, defining a clinical entity
known as Gillespie syndrome (GS [MIM: 206700]).2 GS is
usually diagnosed in the first year of life by the presence
of fixed dilated pupils in a hypotonic infant. Ophthalmo-
logic examination reveals partial aniridia with the pupil
border of the iris containing festooned edge and iris
strands extending onto the anterior lens surface at regular
intervals.3 These eye findings are mandatory to make the
diagnosis of GS because they demonstrate the develop-
mental nature of the iris anomaly, thereby excluding
neurogenic congenital mydriasis in an infant with neuro-
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Since Gillespie’s initial description in 1965, 22 affected
families have been reported.2–19 Current GS-affected fam-
ilies include three sibpairs describing an autosomal-reces-
sive inheritance, two families with disease transmission
from an affected mother to the progeny, and 18 simplex
families in which recessive and dominant de novo muta-
tions might underlie the disease. De novo PAX6mutations
have been identified in two simplex families but otherwise
molecular studies have failed to identify the disease-
causing mutation, supporting genetic heterogeneity of
GS.9,13,15
We collected five trios with index case subjects present-
ing with partial aniridia, cerebellar ataxia, and intellectual
disability with or without additional systemic symptoms
(Table 1 and Figures 1A and 2). Informed consents were
obtained from all the research participants. The study
received approval from the Comite´ de Protection des
Personnes ‘‘Ile-de-France II.’’ Three index case subjects
(F1:II1, F2:II1, F5:II1), one of which was reported previ-
ously (F2:II1),14 were born to consanguineous parents
(Figure 1A). F1:II1, F3:II1, F4:II1, and F5:II1 had neither
point mutations nor micro-rearrangements affecting
PAX6 as determined by Sanger sequencing of the 50 regula-
tory elements,20 the exons and the intron-exon bound-
aries, nor deletions in, or around, PAX6 as determined by
array comparative genomic hybridization and multiplex
ligation-dependent probe amplification (MLPA; SALSA
MLPA kit P219 PAX6, In vitrotek), respectively.
To identify the molecular defect underlying GS, we sub-
jected the genomic DNA (1 mg) from an index case subject
(F1:II1) and her consanguineous parents of Tunisian origin
(F1:I1 and F1:I2) to exome resequencing, using the
SureSelect Human All Exon kit version 5 (Agilent). Each
genomic DNA fragment was analyzed on a sequencer using
the paired-end strategy and an average read length of
75 bases (Illumina HISEQ, Illumina). Image analysis and
base calling were performed with Real Time Analysis
(RTA) Pipeline v.1.9 with default parameters (Illumina). Se-
quences were aligned to the human genome reference
sequence (hg19 assembly) and SNPs were called based on
allele calls and read depth using the CASAVA pipeline
(Consensus Assessment of Sequence and Variation 1.8,
Illumina). Genetic variation annotation was performed
by an in-house pipeline. We first focused our analysis on
consensus splice-site changes, non-synonymous variants,
and insertion and/or deletion in coding regions. Consid-
ering the rarity of the disease and the uncertainmode of in-
heritance, we assumed that the affected individual was
either single heterozygous for a variant absent in parental
DNA (dominant de novo model) and in the Exome Aggre-
gation Consortium (ExAC), 1000 Genomes, dbSNP132,
and Imagine de´ja`-vu databases, or homozygous for a
variant found in the heterozygote state in parental DNA
and absent or with a minor allele frequency < 0.001
in databases (recessive model). This filtering strategy
pointed to one de novo and three homozygous variants
(Tables S1 and S2). The de novo change occurred in KLK9972 The American Journal of Human Genetics 98, 971–980, May 5, 2(c.88C>T [p.Arg30Cys]; GenBank: NM_012315.1), which
encodes the kallikrein-related peptidase 9 (MIM: 605504).
This variant was predicted to be deleterious both by
PolyPhen-2 and SIFT softwares (Table S2), but its frequency
in the ExAC database (7.5:10,000) was significantly higher
than that of Gillespie syndrome, making unlikely its cau-
sality in the disease. Two out of the three homozygote var-
iants were predicted to be benign according to PolyPhen-2
and SIFT and were filtered out (Table S2). The unique re-
maining candidate variant consisted of a nonsense
mutation (c.4672C>T [p.Gln1558*]) in ITPR1 (GenBank:
NM_001099952.2), which encodes the inositol 1,4,5-tri-
sphosphate (IP3) receptor (IP3R), type 1 also known as
IP3R1 (UniProt: Q14643; MIM: 147265) (Tables 2 and S2).
Sanger sequencing confirmed homozygosity and single
heterozygosity of the change in the affected child and
her parents, respectively (Figure 1A).
Three major ITPR1 mRNA isoforms are reported which
in total represents 62 unique exons.21 Variant 1 (GenBank:
NM_001099952.2) includes 59 exons, 57 of which are
coding. Compared to variant 1, variant 2 (GenBank:
NM_0022225) lacks exon 12 whereas isoform 3 (GenBank:
NM_001168272.1) lacks exon 12, uses an alternate in-
frame splice site in intron 23, and includes three additional
exons between variant 1 exons 39 and 40. Sanger
sequencing of the 62 ITPR1 exons and intron-exon bound-
aries (Table S3) detected five additional unique ITPR1 mu-
tations in the other four index case subjects (Table 2 and
Figure 1A). F2:II1, born to consanguineous parents from
Brazil,14 carried another homozygous nonsense mutation
(c.2182C>T [p.Arg728*]) and F3:II1, born to non-consan-
guineous parents from mainland France, had two splice-
sitemutations (c.6366þ3A>Tand c.6664þ5G>T). Segrega-
tion analysis confirmed the biparental transmission in the
two families (Table 2 and Figure 1A). F4:II1, born to non-
consanguineous parents from mainland France, carried a
3-base pair (bp) deletion (c.7687_7689del [p.Lys2563del])
absent from parental DNA. (F4:II1 is the same individual
as 1388_1388 who is described, with the same ITPR1muta-
tion, in the accompanying report by McEntagert et al.22)
Likewise, F5:II1, born to consanguineous parents from
the French Caribbean island La Guadeloupe, carried a
missense change (c.7659T>G [p.Phe2553Leu]) absent in
parental DNA. All variant numbers refer to ITPR1 isoform
1 (GenBank: NM_001099952.2).
The six unique ITPR1 mutations were absent from all
databases and were predicted to be deleterious according
to the Alamut Mutation Interpretation Software, a
decision support system for mutation interpretation based
on Align DGVD, PolyPhen-2, SIFT, SpliceSiteFinder-like,
MaxEntScan, NNSPLICE, and Human Splicing Finder
(Table 2).
ITPR1, ITPR2 (MIM: 600144), and ITPR3 (MIM: 147267)
encode the three subtypes of the IP3-receptor family
(ITPR1, ITPR2, and ITPR3 are also known as IP3R1, IP3R2,
and IP3R3, respectively) that form large (>1 MDa), homo-
and heterotetrameric Ca2þ release channels localized016
Table 1. Clinical Features of the Individuals Affected with Gillespie Syndrome
F1:II1 F2:II114 F3:II1 F4:II1 F5:II1
Age (years) 4.5 16 7.5 18 1.5
Gender F F F F F
Family history no no no no no
Consanguinity yes yes no no yes
Prenatal history persistent truncus
arteriosus
no no no no
Ocular Features
Iris presentation bilateral partial
aniridia
bilateral partial
aniridia
bilateral partial
aniridia
bilateral partial
aniridia
bilateral partial
aniridia
Fundus aspect unremarkable unremarkable unremarkable unremarkable unremarkable
OCT unremarkable unknown unknown unknown unknown
Neurologic Features
Age at onset birth 3 months birth birth birth
Initial symptom hypotonia with
iris hypoplasia
hypotonia with iris
hypoplasia
hypotonia with iris
hypoplasia
hypotonia with iris
hypoplasia
hypotonia with iris
hypoplasia
Cerebellar Signs
Nystagmus Yes yes yes yes yes
Ataxia yes yes yes yes yes
Postural tremor yes unknown yes no unknown
Slurred speech not evaluable yes yes yes unknown
General hypotonia yes yes yes yes yes
Pyramidal sign no unknown no no no
Extrapyramidal sign no unknown no no yes
Peripheral neuropathy no unknown areflexia of lower
limbs
no no
Epileptic seizures no no no no transitory myoclonus
in the neonatal period
Intellectual disability severe (uses two/
three words)
mild (phrases
at 4 years)
moderate no unevaluable
Motor Development
Head control delayed 12 months 18 months 18 months 10 months
Sit without support 3.5 years 3 years 18 months (with
support)
3 years no
Stand with support 4.5 years yes yes 3 years no
Walk unassisted no no no 16 years (a few steps
only)
no
MRI findings unremarkable at
1.5 months; marked
cerebellar atrophy, thin
corpus callosum,
discrete ventricular
dilatation at 4.5 years
reported unremarkable
at ages 6 months and
8 years
moderate cerebellar
atrophy at 2.5 years;
marked cerebellar
atrophy, at 8 years
unremarkable at
6 months; cerebellar
atrophy at 4 years
(vermis > hemispheres)
unremarkable at
3.5 months; marked
cerebellar atrophy at
1.5 years
Other findings hymeneal imperforation facial dysmorphy – short 4th metatarsal marked kyphosis, left
pectoral agenesispredominantly in membranes of endoplasmic reticulum
(ER) Ca2þ stores.23,24 ITPR subtypes are ubiquitously ex-
pressed throughout tissues and all cell types express at least
one subtype. Notably, the majority of cell types outside theThe Amcentral nervous system express multiple isoforms.25–27
Although the expression of various ITPR subtypes is over-
lapping, the expressionof certain subtypes ismore enriched
in a particular tissue to meet the developmental anderican Journal of Human Genetics 98, 971–980, May 5, 2016 973
Figure 1. Recessive and Dominant De Novo ITPR1 Mutations in Families with GS
(A) Pedigree of the families and chromatograms showing the mutations at the genomic level. In families F1, F2, and F3, the affected
individual is homozygous or compound heterozygous for parental mutations whereas in families F4 and F5, the affected individual is
single heterozygous for a mutation absent in parental DNA, suggesting a de novo event.
(B) Agarose gel separation of PCR products obtained from reverse-transcribed leucocyte mRNAs from individuals of family F3 and a con-
trol subject using the following primers: forward (exon 49), 50-caatgcctcgaagttgctc-30 and reverse (exon 53) 50-cgtgggttgtaacccgact-30.
A Formamide gel-loading buffer was used to avoid formation of heteroduplexes. The 605 bp wild-type fragment in the control is seen
in all three members of the family. The presence of this band in II1 demonstrates that both the c.6366þ3A>T and c.6664þ5G>T allow
the production of a wild-type transcript (chromatogram not shown). The mutant mRNA transcribed from the c.6366þ3A>T and
c.6664þ5G>T alleles are seen as additional 543 bp and 615 bp fragments in I1 and II1 and I2 and II1, respectively.
(C) Sanger sequencing of additional 543 and 615 bp fragments amplified from reverse-transcribed mRNAs from individuals of family F3
is consistent with the activation of cryptic splice sites in exon 50 and intron 52, respectively.physiological needsof that tissue. For example, ITPR1 is spe-
cifically enriched in the nervous systemwhereas ITPR2 and
ITPR3 are highly expressed in the digestive system. The
structure of ITPR is generally divided into an N-terminal
ligand-binding domain, a central transducing/modulatory
domain, and a C-terminal channel domain23 (Figure 3A).
IP3, generated after phospholipase C-mediated hydrolysis
of phosphatidyl-inositol 4,5-bisphosphate, engages IP3 re-
ceptors and results in Ca2þ release from ER stores.28
Here we utilized biological samples obtained from GS-
affected individuals and healthy control subjects to
characterize ITPR1 mRNA levels and integrity. Further, we
generated ITPR1 constructs corresponding to mutants
identified in GS-affected individuals and assessed their ac-
tivity in heterologous cell systems. The effect of the
c.4672C>T nonsense mutation and the c.6366þ3A>T
and c.6664þ5G>T splice-site mutations was assessed on
mRNA fromGS-affected individuals and control leucocytes
or immortalized lymphocytes (biological samples from
family 2 individuals were unavailable for analysis). Consid-
ering the c.4672C>T nonsense mutation, wemeasured the
abundance of ITPR1 mRNAs by quantitative reverse-tran-974 The American Journal of Human Genetics 98, 971–980, May 5, 2scription PCR (RT-qPCR) in immortalized lymphocytes of
the homozygous index case subject of family F1 and two
unrelated control subjects. Compared to control subjects,
GS-affected individuals’ lymphoblasts had significantly
reduced levels of ITPR1 mRNAs (mean relative expression
levels of 0.74 5 0.05 and 0.21 5 0.01 in control and GS-
affected individual cell lines, respectively; Figure S1), sug-
gesting degradation through nonsense-mediated mRNA
decay (NMD).
According to the SpliceSiteFinder-like, NNSPLICE, and
Human Splicing Finder prediction softwares, the c.6366þ
3A>T and c.6664þ5G>T mutations identified in family
F3 reduced exons 50 and 52 splice-donor splicing scores
below the scores of neighboring exonic and intronic
cryptic splice-donor sites, respectively (Figure S2). To assess
the activation of these cryptic splice-donor sites, reverse-
transcribed leucocyte mRNAs from F3:II1 and her parents
F3:I1 and F3:I2 were amplified using primers designed in
exons 49 and 53, respectively. Three PCR products were
obtained from F3:II1 reverse-transcribed mRNA which
Sanger sequencing revealed use of both the wild-type
splice-donor sites and neighboring exonic and intronic016
Figure 2. Brain MRI and Eye Findings in Individuals with Muta-
tions in ITPR1
(A–J) MRIs were performed at 1.5 months and 4.5 years, 2.5 and
8 years, 3.5 months and 1.5 years, and 8 years of age in individuals
F1:II1 (A–C), F3:II1 (D–F), F5:II1 (G–I), and F4:II1 (J) by means of
the following modalities: sagittal T1 (A, B, D, E, G, H) or T2 (J)
and axial T2 (C, F, I). In the first months of life, sagittal T1 images
are unremarkable (A, G). The cerebellar atrophy appears with age
as shown on sagittal T1 or T2 images by the moderate atrophy at
age 1.5 years and 2.5 years (**) (D, H) and the marked cerebellar
atrophy at 4.5 and 8 years (**) (B, D, J). In addition to cerebellar at-
rophy, individual F1:II1 presents with thin corpus callosum (*) (B)
and discrete ventricular dilatation (***) (C).
(K) Photograph of an eye of individual F5:II1 showing typical par-
tial iris hypoplasia with iris strands extending onto the anterior
lens surface.cryptic splice-donor sites, respectively (Figures 1B and S2).
Sequencing analysis showed that both the c.6366þ3A>T
and c.6664þ5G>T mutant alleles encoded wild-type and
mutant mRNAs. The mutant mRNA arising from the
c.6366þ3A>T allele lacked the last 62 bp of exon 50
(r.[¼ , 6305_6366del; 6366þ3a>u]; Figure 1B) and was pre-
dicted to encode a truncated ITPR1 (p.Gly2102Valfs5*;
Figure 3B). The mutant transcript arising from the
c.6664þ5G>T allele retained the first 70 bp of intron
52 (r.[ ¼ , 6664_6665ins6664þ1_6664þ70; 6664þ5g>u];
Figure 1B) and was predicted to encode another truncated
ITPR1 (p.Ala2221Valfs23*; Figure 3B). Consistent with
parental genotypes, the shortened and enlarged mutant
mRNA products were specifically detected in the father
and mother leucocytes, respectively (Figure 1B). None of
the aberrant splice products were detected in control indi-
viduals (Figure 1B).
The truncation constructs encompass the ligand-bind-
ing domain and most of the central regulatory domainThe Ambut lack the channel domain. To evaluate the impact of
these mutants on Ca2þ signaling, mammalian expression
vectors co-expressing hcRed and human ITPR1 (ITPR1
WT), ITPR1 p.Gln1558*, ITPR1 p.Gly2102Valfs5*, or
ITPR1 p.Ala2221Valfs23* were created. These truncation
mutants (Figure 3B) were transiently transfected into hu-
man embryonic kidney cell line (HEK293). At 24 hr after
transfection, immunoblot analysis was performed using
antibodies that recognize an epitope located on the N-ter-
minal region of ITPR1. The antibody detected a band cor-
responding to intact endogenous ITPR1 in all lysates
(Figure S3A). The antibody also detected bands of appro-
priate molecular mobility in lysates from cells transfected
with ITPR1 p.Gln1558*, ITPR1 p.Gly2102Valfs5*, and
ITPR1 p.Ala2221Valfs23* but not in cells transfected with
empty vector (Figure S3A). Furthermore, when expressed
in DT40-3KO lymphoma cell line devoid of all three
endogenous ITPRs,29,30 there was no Ca2þ release in
response to IP3 generating stimuli (Figures S3B and S3C),
consistent with the fact that these truncation mutants
lack the channel domain and cannot mediate Ca2þ release.
The truncation fragments represent the soluble part of
the ITPR1 and contain the entire IP3-binding domain
and most, if not all, of the modulatory domain that en-
compasses interaction sites for many regulatory factors.
Accordingly, these mutants might impact endogenous
intact ITPR activities by competing for or sequestering
these factors. Theoretically, this scenario can occur in het-
erozygous states where intact ITPR1 (or even ITPR2 or
ITPR3) and truncation mutants coexist in the same cells.
To evaluate the impact of mutant constructs on Ca2þ
signaling mediated by intact ITPRs, the truncation mu-
tants were transiently transfected into a cell line desig-
nated as HEK-3KO cells. These cells were derived from
HEK293 cells by disrupting all genes encoding IP3R sub-
types using CRISPR/Cas9 editing system (Figure S4).
Compared to DT40-3KO, these cells are easier to transfect
and to manipulate during imaging. An empty vector
(pDC315-hcRed) was used as a control. At 24 hr after trans-
fection, cells were loaded with Ca2þ-sensitive dye Fura-
2AM and stimulated with trypsin to induce Ca2þ release
from internal stores. Trypsin activates a protease-activated
receptor-2 (PAR2), a G-protein-coupled receptor. Consis-
tent with DT40-3KO data, cells expressing truncation
mutants were refractory to stimulation, whereas cells ex-
pressing ITPR1 WT showed robust Ca2þ responses (Figures
S4A and S4B). However, no significant difference between
cells expressing ITPR1 WT alone and cells co-transfected
with ITPR1 WT and various truncation mutants was
observed (Figures S4A and S4B). Altogether, these data
show that the truncation fragments do not affect—either
positively or negatively—Ca2þ release mediated by endog-
enous IP3-receptors under these experimental conditions.
Both p.Lys2563del and p.Phe2553Leu are conserved in
all three ITPR subtypes and they are located in the distal
portion of the sixth membrane-spanning helix or pore-lin-
ing helix that is predicted to project beyond themembraneerican Journal of Human Genetics 98, 971–980, May 5, 2016 975
Table 2. ITPR1 Mutations Identified in the Individuals Affected with Gillespie Syndrome
Pedigree Parental Origin
Allele 1 Allele 2
Mutation (origin) Predicted Effect Mutation (origin) Predicted Effect
Family 1 S, C Morocco c.4672C>T (paternal) p.Gln1558* c.4672C>T (maternal) p.Gln1558*
Family 2 S, C Brazil c.2182C>T (paternal) p.Arg728* c.2182C>T (maternal) p.Arg728*
Family 3 S, NC France c.6366þ3A>T (paternal) p.Gly2102Valfs5*1 c.6664þ5G>T (maternal) p.Ala2221Valfs23*1
Family 4 S, NC France c.7687_7689del (de novo) p.Lys2563del – –
Family 5 S, NC France2 c.7659T>G (de novo) p.Phe2553Leu – –
Abbreviations are as follows: S, simplex family; C, consanguineous; NC, nonconsanguineous.
1Predicted from mRNA analysis. Nucleotide positions according to the reference sequence GenBank: NM_001099952.2. The p.Phe2553Leu changes was pre-
dicted to be deleterious according to PolyPhen-2, SIFT, and Mutation Taster available through the Alamut Interpretation Software 2.0.
2French Caribbean Island La Guadeloupe.to the cytosol. This region of the receptor is believed to be
critical for channel gating. To begin to assess the effect of
these mutations on ITPR channel activity, ITPR1 WT was
mutated by PCR to make ITPR1 p.Lys2563del and was
transfected into DT40-3KO to generate stable cell lines.
Figure S5A shows that anti-ITPR1 detected single bands
in cells transfected with ITPR1WTand ITPR1 p.Lys2563del
constructs, corresponding to intact ITPR1, but no immu-
noreactivity was detected in DT40-3KO lysates. Tomeasure
intracellular Ca2þ release, cells were loaded with Fura-2AM
and stimulated with 500 nM trypsin to activate the prote-
ase-activated receptor and induce IP3 formation. As shown
previously, DT40-3KO cells do not respond to trypsin acti-
vation because they lack all three endogenous ITPRs.29 In
contrast, stimulation of ITPR1WTexpressing cells induced
amarked Ca2þ peak (Figures S5B and S5C). Cells expressing
ITPR1 p.Lys2563del were not responsive, even to higher
concentrations of trypsin (Figures S5B and S5C). In addi-
tion, the resting [Ca2þ] was not significantly different in
DT40-3KO or in DT40-3KO expressing wild-type human
ITPR1 or ITPR1 p.Lys2563del, indicating that these
proteins do not perturb the integrity of intracellular stores
(basal fluorescence 0.3985 16.8 in ITPR1WTand 0.3795
4.34 in ITPR1 p.Lys2563del cells). In total, the above
findings indicate that ITPR1 p.Lys2563del do not form
functional calcium release channels when produced in
isolation in DT40-3KO cells.
To determine whether the assembly of ITPR1
p.Lys2563del into tetramers containing wild-type ITPR1
subunits affects the activity of channels formed,
ITPR1 p.Lys2563del and ITPR1 WT were transfected either
alone or in combination into HEK-3KO cells. When wild-
type and mutant subunits are co-produced in the same
cell, it would be predicted that they might associate or
co-assemble into tetrameric channels. However, because
the association or oligomerization is probably random,
the number of wild-type and mutant subunits in the tetra-
meric channels formed in cells transfected with multiple
cDNAs is difficult to predict. Initial experiments co-ex-
pressing ITPR1 p.Lys2563del and ITPR1 WT cDNA at 1:1
or 2:1 ratio cDNA indicated that mutant subunits did not976 The American Journal of Human Genetics 98, 971–980, May 5, 2appear to markedly alter calcium release (Figures S6A and
S6B). We reasoned that increasing the amount of mutant
subunit would favor the formation of tetrameric channels
incorporating mutant subunits. Therefore, to increase the
likelihood that most assembled channels incorporate
mutant subunits, an ITPR1 p.Lys2563del to ITPR1WTratio
of 6:1 was used per transfection. Protein levels produced
from the transfected constructs were verified via immuno-
blot analyses and Figure 4A shows that anti-ITPR1-detected
single bands in HEK-3KO cells transfected with ITPR1 WT
and ITPR1 p.Lys2563del corresponding to intact ITPR1,
but no immunoreactive band was detected in HEK-3KO ly-
sates transfected with empty vector. As expected, stimula-
tion of HEK-3KO cells with 500 pM trypsin did not result
in Ca2þ release, because they lack all three endogenous
IP3Rs. In contrast, stimulation of HEK-3KO transfected
with ITPR1 WT alone induced a marked Ca2þ peak
(Figures 4B and 4C). Interestingly, co-expression of ITPR1
p.Lys2563del and ITPR1 WT cDNAs resulted in inhibition
of both the amplitude of calcium signal (Figures 4B and
4C) and the percentage of responding cells (5.66% 5
1.46% in co-transfected cells compared to 20.71% 5
2.11% in cells transfected with ITPR1 WT only). The
simplest interpretation of these data is that ITPR1 channels
incorporating one or more mutant subunits are not func-
tional. The fact that more mutant cDNA was required to
see the inhibitory effect might suggest that numerous sub-
units are required to assemble into a tetrameric channel to
render it dysfunctional. Alternatively, it is possible that the
mutant subunit does not favor oligomerization or associa-
tion with the wild-type subunits and thus a higher propor-
tion of mutant subunits are necessary to increase the
probability of this association.
Here, we report that both recessive and dominant ITPR1
mutations cause Gillespie syndrome. ITPR1 is a predomi-
nant isoform in the brain among the three types of ITPRs
and is strongly expressed in cerebellar Purkinje cells.31
Mice with complete homozygosity for Itpr1 ablation
suffer from severe epilepsy and ataxia and die either in
utero or before weaning.32 Consistently, ITPR1 mutations
have been reported to cause cerebellar diseases including016
Figure 3. Schematic Diagrams Depicting
Full-Length ITPR1 and ITPR1 Mutation
Associated with Human Diseases
(A) The panel displays the functional do-
mains of ITPR1. Shown are point muta-
tions associated with spinocerebellar
ataxia or ataxic cerebellar palsy (blue) or
Gillespie syndrome not investigated in
this study (red).
(B) The lower four panels show the
truncation mutants and p.Lys2563del
mutant expressed in heterologous cell sys-
tems for functional analysis. The black
boxes of the ITPR1 p.Gly2102Valfs5* and
ITPR1 p.Ala2221Valfs23* mutants depict
the VGSA and VGFQRISNNTERHSS-
GISQTWA amino acid sequences intro-
duced by the c.6366þ3A>T and
c.6664þ5G>T, respectively.late-onset spinocerebellar ataxia type 15 (SCA15 [MIM:
606658]),33 congenital nonprogressive spinocerebellar
ataxia and mild cognitive impairment (SCA29 [MIM:
117360]),34 infantile-onset cerebellar ataxia with mild
cognitive deficit,35 and childhood-onset ataxic cerebellar
palsy with moderate intellectual disability36 (see ITPR1
schematic diagram in Figure 3A).
Affected individuals had similar iris anomalies and
neonatal ataxia with progressive cerebellar atrophy (Fig-
ure 2). Moderate to severe intellectual disabilities were
noted in the three individuals with recessive mutations
(F1:II1, F2:II1, and F3:II1; Table 1). In contrast, the affected
individual F4:II1 aged 18 years and harboring the de novo
c.7687_7689del mutation was reported to have normal
intelligence (Table 1). It will be interesting to follow the
intellectual development of the second individual with a
heterozygous de novo mutation to determine whether
some genotype-phenotype correlations can exist (F5:II1,
age 1.5 years; c.7659T>G).
All individuals with adult-onset SCA15 but one show
heterozygosity for partial 3 pter deletions encompassing
ITPR1 (or at least the 50 region of the gene).33 The four
ITPR1 mutations identified in GS-affected families F1–F3
are predicted to introduce a premature translation termina-
tion codon. Intriguingly, none of the heterozygous parents
in families F1 and F3 (F2 unavailable) had neurologic
symptoms, as assessed by clinical examination and 3 Tesla
cerebral RMN imaging (Figure S7). It cannot be excluded
that some or all these heterozygous individuals whose
age ranged from 35 to 44 years might develop cerebellar
symptoms later in life. However, it is also quite possible
that they harbor mutations that are not as detrimental as
gene ablation. The fact that homozygosity for null alleles
is incompatible with a prolonged life in Itpr1/ mouse32
and the Italian Spinone with spinocerebellar ataxia37 but
not in individuals with Gillepsie syndrome is consistent
with this hypothesis. In addition, mRNA analysis in family
F3 demonstrated that both parents carry an intronic muta-
tion that allows for the production of the wild-type mRNAThe Amfrom the mutant allele. The Purkinje cells of these individ-
uals are likely to produce more ITPR1 than that of individ-
uals with adult-onset cerebellar ataxia due to gene
ablation, thereby bypassing the Ca2þ release defect. Along
the same lines, premature termination codon (PTC) self-
correcting mechanisms might have occurred in the
Purkinje cells of individuals F1:I1, F1:I2, F2:I1, and F2:I2
harboring the c.4672C>T and c.2182C>T truncating mu-
tations, respectively. These mechanisms include transla-
tional read-through that has recently been reported to be
more abundant than expected in higher species, including
human.38 Nonsense-associated altered splicing (NAS)39–42
and basal exon skipping (BES),43,44 which allow selective
exclusion of an in-frame exon with a premature termina-
tion codon, are other correcting mechanisms that have
recently been shown to modulate disease severity in hu-
man.43–45
Although experiments presented here did not show
a clear impact of the p.Gln1558*, p.Gly2102Valfs5*,
and p.Ala2221Valfs23* truncated ITPR1s on the Ca2þ
release activity of channels assembled from wild-type
ITPRs in HEK293 cells, it cannot be formally excluded
that mutant proteins could functionally interact in vivo
with wild-type ITPR channels and modulate their
function.
Unlike adults affected with SCA15 who consistently
carry null ITPR1 alleles, children with early-onset cere-
bellar ataxia andmoderate cognitive disability consistently
carry missense ITPR1 mutations affecting the conserved
IP3-binding domain or modulatory domain. Because ITPR
channels can be homo- or heteromeric, it can be envi-
sioned that ITPR channels are assembled from various
combination of mutant ITPR1 (and wild-type in case of
heterozygous state) as well as ITPR2 and ITPR3 subunits.
How the incorporation of mutant ITPR1 affects channel
activity probably depends on the severity or location of
the mutation as well as on the stoichiometry of mutant
subunits assembled within the tetrameric channel. It has
been suggested that these mutations, most of whicherican Journal of Human Genetics 98, 971–980, May 5, 2016 977
Figure 4. Production of the ITPR1 p.Lys2563del Mutant in
HEK-3KO and Evaluation of Its Effect on the Formation of ITPR1
Channels
(A) HEK-3KO cells were transfected as indicated. Lysates were pre-
pared from transfected cells, quantified and equivalent amounts of
proteins were separated on 4% SDS-PAGE and processed in immu-
noblots using a rabbit polyclonal antibody raised against the most
carboxyl-terminal 19 amino acid residues of ITPR1 (generated on
demand; Pocono Rabbit Farms and Laboratories). A representative
experiment is shown. Lysates from WT-HEK, naive HEK293 cells,
were used as a control.
(B) HEK-3KO cells grown on coverslips were transfected with
2.4 mg empty vector or cDNA coding for ITPR1 p.Lys2563del either
alone or with 0.4 mg ITPR1 WT as indicated. The total amount of
DNA was kept constant by adding empty vector. At 24 hr after
transfection, cells were loaded with Fura-2AM and stimulated
with 500 pM trypsin to induce IP3 formation. Ca
2þ release was
determined as a change in the 340/380 fluorescence ratios. Fluo-
rescent ratios were normalized to the ratios from the first 5 s after
the start of run. Shown are representative traces.
(C) Bar graphs depict the average maximum change over basal
340/380 fluorescence ratios resulting from trypsin stimulation of
cells expressing the indicated constructs. Experiments were
repeated at least three times. Data are presented as mean5 SE.occurred de novo, might exert a dominant-negative effect,
possibly disrupting cellular calcium homeostasis.35 Inter-
estingly, the two de novo mutations identified in individ-
uals with GS affect the distal portion of the S6 pore-lining
helix that is pivotal for channel gating and where no dis-
ease-associated mutation has been reported to our knowl-978 The American Journal of Human Genetics 98, 971–980, May 5, 2edge. Co-expression of the ITPR1 p.Lys2563del mutant
construct with the wild-type counterpart resulted in
altered calcium release, strongly supporting the view that
the mutation exerts a dominant-negative effect. Studies
wherein the exact subunit composition of tetrameric chan-
nels is predetermined46 are required to define how many
ITPR1 p.Lys2563del subunits per channel are necessary
to exert the dominant-negative effect or disable the chan-
nel activity.
To our knowledge, no abnormality in eye development
has been described in heterozygous ITPR1-related individ-
uals with SCA, the Itpr1 knock-out mouse,32,47 the natu-
rally occurring Itpr1opt/opt mouse,48 or the Italian Spinone
with spinocerebellar ataxia.37 Given that minor ocular
symptoms could be overlooked, ophthalmological exami-
nations including gonioscopy and funduscopy were un-
dertaken in parents of individuals with GS (families 1
and 3) and in two brothers with SCA15 harboring a large
gene deletion.49 None of the individuals had any ocular
symptom, supporting the view that expression of one
wild-type allele is sufficient to allow proper eye develop-
ment in these individuals.
There is accumulating evidence for the involvement of
Ca2þ in developmental events and gene expression.
Furthermore, ITPRs have proven important in early
embryogenesis, in particular to determine the dorso-
ventral axis formation.50 The role of ITPR1 in eye develop-
ment has not been documented thus far. In the
Drosophila, however, it has been reported that the uni-
que IP3R isoform (DmIP3R) is detected ubiquitously
throughout development51–53 and is essential for embry-
onic and larval development. In Ip3r mutants, maternal
Ip3r mRNA is sufficient for progression through the em-
bryonic stages, but larval organs show asynchronous
and defective cell divisions and imaginal discs arrest early
and fail to differentiate.54 Adult mosaic Drosophila con-
taining homozygous Insp3 mutant photoreceptors in an
otherwise wild-type genetic background have been
created, the analysis of which revealed disruptions of
the onomatidal architecture and retinal degeneration,
demonstrating a role in eye function.54 Hopefully, fur-
ther studies in vertebrate animals will allow researchers
to substantiate the role of ITPR1 in the development of
the eye.
In summary, we report on biallelism or single heterozy-
gosity for ITPR1 mutations in 5/5 index case subjects
with Gillespie syndrome. These findings demonstrate the
long-suspected co-existence of autosomal-recessive and
autosomal-dominant patterns of inheritance of Gillespie
syndrome and further extend the spectrum of ITPR1 defi-
ciencies in the eye.Supplemental Data
Supplemental Data include seven figures and three tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
ajhg.2016.03.004.016
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